STAT1 and inflammatory bowel disease: Our data also recommend sex stratification prior to evaluation of therapeutic efficacy of JAK‐STAT inhibitors in IBD patients (Sandborn et al., 2012, 2014) to account for sex‐specific STAT1 effects on inflammation.